We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $767M
1-Year Est. Return 119.71%
This Fund
S&P 500
This Quarter Est. Return
+8.44%
1 Year Est. Return
+119.71%
3 Year Est. Return
+244.81%
5 Year Est. Return
+382.5%
10 Year Est. Return
+2,655.81%
AUM
$1.48B
AUM Growth
+$175M
Cap. Flow
-$85.7M
Cap. Flow %
-5.8%
Top 10 Hldgs %
38.11%
Holding
211
New
41
Increased
36
Reduced
32
Closed
77

Top Buys

Rank Stock Value
1
AZN icon
AstraZeneca
AZN
+$10.3M
2
IOVA icon
Iovance Biotherapeutics
IOVA
+$9.84M
3
HOWL icon
Werewolf Therapeutics
HOWL
+$9.68M
4
ALT icon
Altimmune
ALT
+$9.34M
5
TWLO icon
Twilio
TWLO
+$9.2M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$49.7M
2
ABBV icon
AbbVie
ABBV
+$26.3M
3
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$12.9M
4
BMY icon
Bristol-Myers Squibb
BMY
+$12.6M
5
PANW icon
Palo Alto Networks
PANW
+$10.4M

Sector Composition

Rank Sector Weight
1 Healthcare 55.27%
2 Miscellaneous 26%
3 Technology 8.46%
4 Industrials 5.02%
5 Financials 2.2%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBTG icon
126
American Express Global Business Travel
GBTG
$4.94B
$714K 0.05%
73,055
-76,945
-51% -$758K
TWNI.U
127
DELISTED
Tailwind International Acquisition Corp. Units, each consisting of one Class A ordinary share and one-third of one redeemable warrant
TWNI.U
$483K 0.03%
48,342
-101,658
-68% -$1.01M
ELEV
128
DELISTED
Elevation Oncology
ELEV
$407K 0.03%
+30,000
New +$371K
IMTXW
129
DELISTED
Immatics N.V. Warrants
IMTXW
$344K 0.02%
100,000
– –
MGIC
130
DELISTED
Magic Software Enterprises
MGIC
$259K 0.02%
+15,976
New +$256K
SRSA
131
DELISTED
Sarissa Capital Acquisition Corp. Class A Ordinary Shares
SRSA
$237K 0.02%
23,900
– –
CERE
132
DELISTED
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
$236K 0.02%
9,212
-903,028
-99% -$12.9M
OTLKW
133
DELISTED
Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022
OTLKW
$49K ﹤0.01%
129,500
– –
ATXS
134
DELISTED
Astria Therapeutics
ATXS
– –
-215,667
Closed -$3.74M
BBIO icon
135
BridgeBio Pharma
BBIO
$13.2B
– –
-23,890
Closed -$1.47M
BIDU icon
136
Baidu
BIDU
$30.7B
– –
-25,000
Closed -$5.44M
BMY icon
137
Bristol-Myers Squibb
BMY
$128B
– –
-200,000
Closed -$12.6M
BOLT icon
138
Bolt Biotherapeutics
BOLT
$6.45M
– –
-12,050
Closed -$7.93M
CAMT icon
139
Camtek
CAMT
$6.73B
– –
-79,746
Closed -$2.38M
CLDX icon
140
Celldex Therapeutics
CLDX
$3.06B
– –
-220,320
Closed -$4.54M
CLOU icon
141
PUT
Global X Cloud Computing ETF
CLOU
$367M
– –
-170,600
Closed -$4.39M
CNTB
142
Connect Biopharma Holdings
CNTB
$81.2M
– –
-50,000
Closed -$925K
COGT icon
143
Cogent Biosciences
COGT
$5.76B
– –
-762,569
Closed -$6.7M
CYBR
144
DELISTED
CyberArk
CYBR
– –
-55,000
Closed -$7.11M
EQ icon
145
Equillium
EQ
$120M
– –
-254,184
Closed -$1.82M
EWTX icon
146
Edgewise Therapeutics
EWTX
$5.1B
– –
-100,000
Closed -$3.25M
DMRA
147
Damora Therapeutics
DMRA
$1.41B
– –
-17,921
Closed -$2.72M
HIPO icon
148
Hippo Holdings
HIPO
$844M
– –
-18,720
Closed -$4.68M
ICLN icon
149
PUT
iShares Global Clean Energy ETF
ICLN
$2.11B
– –
-420,000
Closed -$10.2M
IFRX icon
150
InflaRx
IFRX
$304M
– –
-1,000,000
Closed -$3.9M
4 5
6
7 8

Similar funds

ISWM
Independent Solutions Wealth Management Williamsville, New York $766M AUM 31.53% 1-Year Est. Return
ACP
Albar Capital Partners London, United Kingdom $767M AUM 61.96% 1-Year Est. Return
NIM
Nexus Investment Management Toronto, Ontario, Canada $767M AUM 30.97% 1-Year Est. Return
ACM
Arvin Capital Management Austin, Texas $766M AUM 36.51% 1-Year Est. Return
CBT
Crews Bank & Trust Wauchula, Florida $766M AUM 19.5% 1-Year Est. Return
SPIA
Strategic Point Investment Advisors Providence, Rhode Island $767M AUM 17.58% 1-Year Est. Return
CNB
Camden National Bank Camden, Maine $767M AUM 14.32% 1-Year Est. Return
HI
Hendershot Investments Centreville, Virginia $766M AUM 10.81% 1-Year Est. Return

Sphera Funds Management's Q2 2021 Portfolio in Review

As of Q2 2021, Sphera Funds Management held 211 positions worth $1.48B, up 13% from $1.3B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Sphera Funds Management withdrew a net $85.7M in Q2 2021, closing 77 positions and reducing 32 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $12.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 63% a quarter earlier, followed by Miscellaneous and Technology.

Against the trend, Sphera Funds Management opened a new position in Iovance Biotherapeutics worth $9.85M.

  • Sphera Funds Management's largest Q2 2021 buy was Iovance Biotherapeutics: 378,642 shares worth $9.85M.
  • Sphera Funds Management added most to AstraZeneca in Q2 2021, an estimated $10.3M increase.
  • Sphera Funds Management's biggest Q2 2021 reduction was Eli Lilly, cutting an estimated $49.7M.
  • Sphera Funds Management fully exited Bristol-Myers Squibb in Q2 2021, selling an estimated $12.6M.
  • Sphera Funds Management's ten largest holdings make up 38% of its $1.48B portfolio in Q2 2021.
  • Sphera Funds Management opened 41 new positions and closed 77 in Q2 2021.
  • Sphera Funds Management's portfolio value rose 13% quarter-over-quarter to $1.48B.

Based on Sphera Funds Management's 13F filing for Q2 2021, filed 17 Aug 2021.